Vitamin K2 could be novel therapeutic target for common cardiovascular condition

ba04826b-fcc6-419b-b99f-6604a2724b70articleimage.jpg

23 Nov 2017 --- The European Heart Journal has published a review paper that highlights the potential of vitamin K2 supplementation for calcific aortic valve stenosis (CAVS), a common cardiovascular condition in the aging population where no medical therapy currently exists.

According to researchers, once symptomatic severe CAVS has developed, there is a dismal prognosis without intervention. Currently, the only treatment for (symptomatic) severe CAVS is surgical or trans catheter aortic valve replacement (AVR), but it is an intervention to which not all patients are suited.

While multiple trials have attempted to repurpose commonly used pharmacological interventions to slow CAVS progression, pharmacological interventions have thus far failed to alter the course of CAVS. The review paper notes that studies have demonstrated that statins, widely used for lipid lowering in atherosclerosis and inflammation, have no effect on CAVS progression or clinical outcomes, and might actually exacerbate the condition.

However, the researchers noted promise with vitamin K2, specifically the long-chain menaquinones (MK7), as they are transported efficiently beyond the liver. “Vitamin K supplementation is an attractive option to replenish vascular vitamin K stores to ensure optimal calcification inhibition,” the researchers write.

“Recognizing that medical therapies are proving ineffective, researchers are shining a light on efficacious supplemental alternatives, which leads them to the clinical research that NattoPharma has spearheaded,” says Dr. Hogne Vik, Chief Medical Officer with Norwegian-based NattoPharma ASA, a company targeting vitamin K2 research and development. 

“Specifically, our three-year cardiovascular study in healthy postmenopausal women taking just 180 mcg daily of Vitamin K2 as MK-7 (as MenaQ7) demonstrated a cessation and even regression in arterial stiffness,” Dr. Vik adds. “The relevance of our three-year study has resulted in several studies by the medical community for patients with existing coronary artery calcification, aortic valve calcification, and peripheral artery calcification.”

The review paper concludes: “The pathophysiological mechanisms involved in CAVS initiation and progression are being rapidly elucidated and include inflammation, fibrosis, and calcification. With this advancing knowledge, we have identified novel therapeutic targets like vitamin K and new imaging techniques that can be used to test the efficacy of novel agents and further inform our pathophysiological understanding.”

In an interview with NutritionInsight earlier this year, Eric Anderson, Senior Vice President of Global Marketing and Business Development at NattoPharma, underlined the company’s commitment to supporting research into the benefits of vitamin K. “When we look at vitamin K2 as menaquinone-7, we believe this is everything that is good about the natural products industry,” Anderson said. “Researchers discovered K2, and NattoPharma supported its substantiation.”

“We’re only supplying the active, menaquinone/vitamin K2; these studies are being paid for by traditional medical doctors who are treating diseased patients, and the only active is a vitamin,” Anderson said. “That’s what it really should be about: You have science, science leads to discovery, which in turn leads to an investment into proving that [an active] works as a dietary supplement.”

References:
Peeters FECM, et al. Calcific aortic valve stenosis: hard disease in the heart. Euro Heart J (2017) 0,1-8.
Knapen MHJ, et al. Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women: double-blind randomised clinical trial. Thrombosis and Haemostasis (2015) 19;113(5).

Related Articles

Nutrition & Health News

Yogurt may reduce cardiovascular disease risk

19 Feb 2018 --- A higher yogurt intake is associated with lower cardiovascular disease risk among hypertensive men and women, a study in the American Journal of Hypertension suggests. High blood pressure is a major cardiovascular disease risk factor. Clinical trials have previously demonstrated beneficial effects of dairy consumption on cardiovascular health, and yogurt may independently be related to cardiovascular disease risk.

Nutrition & Health News

Saturated fat and sugar can cause depression and anxiety: study

14 Feb 2018 --- A diet rich in saturated fat, such as palm oil, and sugar not only leads to obesity, but it also creates inflammation in the nucleus accumbens, a part of the brain that controls mood and the feeling of reward. This inflammation can lead to depressive, anxious and compulsive behavior and disrupt metabolism, according to a study from the University of Montreal Hospital Research Centre (CRCHUM). The discovery illustrates the vicious circle experienced by people with obesity caused by a diet rich in sugar and saturated fat, with their diet leading to negative emotions, which can stimulate the quest for more comfort through food.

Nutrition & Health News

EID Parry and Synthite Industries partner on phycocyanin production 

08 Feb 2018 --- Enhanced health company Valensa International has entered into a joint venture agreement between Valensa’s parent company EID Parry and Synthite Industries Ltd, which promises to boost microalgae extracts for nutraceutical applications. It involves a US$6.5 million investment in an India-based manufacturing facility for the extraction of Parry Organic Spirulina to produce Phycocyanin, which Valensa will be developing for dietary supplements, functional and medical foods.

Nutrition & Health News

Aronia as a trending superfruit: RTD start-up ax-water's infused waters

07 Feb 2018 --- Native to the Midwest region of North America, but still largely unknown in the US, the aronia berry is the nutrient-packed superfood for which the consumer health industry has been waiting. This is according to ax-water, a US health and wellness beverage company cornering this new market in the US with a range of aronia berry infused waters. NutritionInsight spoke with Blake Johnson, agriculture and biosystems engineer and Co-Founder of ax-water, about the merits of this “superfruit.”

Nutrition & Health News

Arjuna ups sustainability credentials by improving nitric oxide booster production process

05 Feb 2018 --- Arjuna Natural Extracts has implemented a sustainable approach to meet growing demand for its nitric oxide booster, OxyStorm, in the US and Europe. The company reports it is now able to guarantee a sustainable, nitrate-enriched, all-natural Amaranthus extract supply for boosting nitric oxide levels. 

More Articles
URL : http://www.nutritioninsight.com:80/news/vitamin-k2-could-be-novel-therapeutic-target-for-common-cardiovascular-condition.html